布勒维肽单药治疗HDV相关肝硬化患者长达96周的真实世界有效性和安全性
这项欧洲回顾性多中心真实世界研究纳入244例HDV相关肝硬化患者,接受布勒维肽2 mg/日单药治疗中位92周。第96周病毒学、生化学和联合应答率分别为79%、64%和54%,肝功能指标和肝硬度改善,新发HCC和失代偿累积风险分别为3.0%和2.8%,仅10%出现轻度一过性瘙痒。
要点
- 布勒维肽2 mg/日单药治疗HDV相关肝硬化长达96周安全有效,病毒学和临床应答随时间增加。
- 第96周病毒学、生化学和联合应答率分别为79%、64%和54%。
- 第96周新发HCC和失代偿累积风险分别为3.0%(95%CI 2-6%)和2.8%(95%CI 1-5%)。
核心结论
- 布勒维肽2 mg/日单药治疗HDV相关肝硬化长达96周安全有效,病毒学和临床应答随时间增加,肝脏相关并发症发生率低。
研究设计与样本
- 欧洲回顾性多中心真实世界研究(SAVE-D),连续纳入自2019年9月起开始布勒维肽2 mg/日治疗的HDV感染肝硬化患者244例,中位治疗92周(IQR 71-96)。
主要发现
- 第48周和第96周病毒学应答率分别为65%和79%,生化学应答率分别为61%和64%,联合应答率分别为44%和54%。
- 治疗期间AST、GGT、白蛋白、IgG和LSM值显著改善。
- 多数患者血清胆汁酸水平升高,但仅10%报告轻度一过性瘙痒,且与胆汁酸水平无关。
- 第96周新发HCC和失代偿累积风险分别为3.0%(95%CI 2-6%)和2.8%(95%CI 1-5%)。
- 13例(5%)患者接受肝移植(其中11例因HCC,2例因失代偿)。
关键数值与推荐
- 基线中位年龄49岁(IQR 40-58),男性61%;中位ALT 80 U/L(IQR 55-130),中位LSM 18.3 kPa(IQR 13.0-26.3),中位血小板计数94×10³/mm³(IQR 67-145)。
- 54%有食管静脉曲张,95%为Child-Pugh A级肝硬化,10%合并HIV感染,92%正在使用核苷(酸)类似物。
- 基线中位HDV RNA为5.4 log10 IU/ml(IQR 4.1-6.5),中位HBsAg为3.8 log10 IU/ml(IQR 3.4-4.1)。
临床怎么用
- 布勒维肽2 mg/日单药治疗在HDV相关肝硬化患者(包括临床显著门静脉高压患者)中安全有效,肝功能检查和肝硬度改善提示晚期肝病患者的潜在临床获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Bulevirtide (BLV) 2 mg/day is EMA approved for the treatment of compensated chronic HDV infection; however, real-world data in large cohorts of patients with cirrhosis are lacking. METHODS: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day from September 2019 were included in a European retrospective multicenter real-world study (SAVE-D). Patient characteristics before and during BLV treatment were collected. Virological, biochemical, combined responses, adverse events and liver-related events (hepatocellular carcinoma [HCC], decompensation, liver transplant) were assessed. RESULTS: A total of 244 patients with HDV-related cirrhosis receiving BLV monotherapy for a median of 92 (IQR 71-96) weeks were included: at BLV start, median (IQR) age was 49 (40-58) years and 61% were men; median ALT, LSM and platelet count were 80 (55-130) U/L, 18.3 (13.0-26.3) kPa, and 94 (67-145) x103/mm3, respectively; 54% had esophageal varices, 95% Child-Pugh A cirrhosis, and 10% HIV coinfection; 92% were on nucleos(t)ide analogues; median HDV RNA and HBsAg were 5.4 (4.1-6.5) log10 IU/ml and 3.8 (3.4-4.1) log10 IU/ml, respectively. At weeks 48 and 96, virological, biochemical and combined responses were observed in 65% and 79%, 61% and 64%, 44% and 54% of patients, respectively. AST, GGT, albumin, IgG and LSM values significantly improved throughout treatment. Serum bile acid levels increased in most patients, but only 10% reported mild and transient pruritus, which was independent of bile acid levels. The week 96 cumulative risks of de novo HCC and decompensation were 3.0% (95% CI 2-6%) and 2.8% (95% CI 1-5%), respectively. Thirteen (5%) patients underwent liver transplantation (n = 11 for HCC, n = 2 for decompensation). CONCLUSION: BLV 2 mg/day monotherapy for up to 96 weeks was safe and effective in patients with HDV-related cirrhosis. Virological and clinical responses increased over time, while the incidence of liver-related complications was low. IMPACT AND IMPLICATIONS: Bulevirtide 2 mg/day is EMA approved for the treatment of compensated chronic hepatitis delta; however, real-world data in large cohorts of patients with cirrhosis are lacking. Bulevirtide 2 mg/day monotherapy for up to 96 weeks was safe and effective (week 96: 79% virological, 64% biochemical and 54% combined response) in a large real-world cohort of patients with HDV-related cirrhosis, including patients with clinically significant portal hypertension. Liver function tests and liver stiffness improved, suggesting a potential clinical benefit in patients with advanced liver disease, while the incidence of de novo liver-related events (hepatocellular carcinoma and decompensation) was low during the 96-week study period.
引用
- Degasperi E, Anolli MP, Jachs M, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. J Hepatol. 2025. PMID: 39793613. doi:10.1016/j.jhep.2024.12.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。